Survodutide 10mg

Survodutide is a dual agonist of the GLP-1 and glucagon receptors, originally developed as a treatment for Type-2 Diabetes and obesity. Like other GLP-1 drugs, it suppresses appetite, increases fat oxidation, and supports metabolic activity. Survodutide has also shown promise as a treatment for non-cirrhotic metabolic-dysfunction-associated steatohepatitis (MASH) and moderate liver fibrosis (F2–F3 stage).

Benefits

• At 46 weeks, participants lost an average of 6 inches from waist circumference
• 19% total body weight loss at 4.8mg weekly
• Significant reduction in blood pressure at 2.4mg or higher
• Potentially beneficial for cardiovascular health
• Ongoing weight loss past 46 weeks suggests longer-term use may yield greater fat reduction

Possible Side Effects

Survodutide shows milder side effects than other GLP-1 drugs in clinical trials. Reported side effects include:

• Injection site irritation (redness, swelling, itching)
• Nausea
• Vomiting
• Diarrhea

Contraindications

• Monitor patients on antihypertensive medications — Survodutide may interact with blood pressure meds
• Do not take if pregnant or breastfeeding
• Do not stop all blood pressure meds without consulting a physician — this may offset Survodutide’s benefits

Stacking Suggestions

• Tirzepatide or Semaglutide (alternate between cycles to prevent GLP-1 receptor desensitization)
• NAD+ or MOTS-C – enhances cellular energy production and mitochondrial repair alongside fat loss
• AOD-9604 – further supports lipolysis during Survodutide’s appetite-suppressing phase
• L-Carnitine Injections – promotes fat transport into mitochondria for oxidation
• Glutathione – reduces oxidative stress and supports liver function (especially in MASH patients)
• CJC-1295/Ipamorelin – enhances lean muscle gain during weight loss phases

For metabolic and liver optimization, Survodutide + Glutathione + NAD+ is a powerful triad. For fat loss, stack with AOD-9604 and CJC-1295/Ipamorelin to preserve lean mass and recover faster.